Notably, FOXO1 expression was significantly lower in patients with intermediate or high-risk ALL than in ETV6-RUNX1 ALL, a well-known excellent prognosis group (Figure 3B and Supplementary Figure 6). This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.